Investigation of hearing loss in patients with acute brucellosis by standard and high-frequency audiometry  by Kaygusuz, T. Ozturk et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01167.x
Investigation of hearing loss in patients with acute brucellosis by standard
and high-frequency audiometry
T. Ozturk Kaygusuz1, I. Kaygusuz2, S. S. Kilic3, S. Yalcin2 and S. Felek3
1Department of Infectious Diseases and Clinical Microbiology, Government Hospital, 2Department of
Otorhinolaryngology and 3Department of Infectious Diseases and Clinical Microbiology, Medical
Faculty, Firat University, Elazig, Turkey
ABSTRACT
This study aimed to determine the effect of acute brucellosis on the auditory system. Forty-two patients
with acute brucellosis were evaluated clinically, and with serological and audiological tests, before and
after treatment. Hearing threshold averages were calculated at 11 different frequencies (250–8000 Hz) of
the auditory airway, and statistical analysis was performed. The average hearing thresholds were
> 20 dB, with standard audiometry at 6000–8000 Hz, and < 20 dB at all other frequencies. After
treatment, the average auditory threshold decreased to < 20 dB at 6000–8000 Hz (p < 0.0001). Pure-tone
hearing thresholds were improved at all frequencies after treatment, with statistically significant
differences at all frequencies except 12 000, 14 000 and 16 000 Hz (p < 0.05). There was no permanent
hearing loss caused by acute brucellosis, and hearing thresholds were restored after treatment. It was
concluded that acute brucellosis affects the auditory system, especially at high frequencies, and that
patients with all forms of brucellosis should be evaluated for hearing loss.
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INTRODUCTION
Brucellosis is a frequent cause of morbidity and
mortality in humans and animals, with an
estimated half a million new cases annually
[1]. The disease is primarily a zoonotic infection
that can be transmitted to humans by direct
contact with infected animals, products of con-
ception or animal discharges, and by consump-
tion of potentially infected milk, milk products
or meat [2]. The incidence of the disease has
decreased markedly in industrialised countries,
but it remains a major public health problem in
many developing countries. Of the six known
species of Brucella, only four (Brucella melitensis,
Brucella abortus, Brucella suis and Brucella canis)
are known to infect humans. B. melitensis is the
most frequent cause of brucellosis in humans,
and is found mainly in Latin American, Medi-
terranean and Arabian countries [3,4].
The clinical manifestations of acute brucellosis
are variable and non-specific, but the most fre-
quent are fever, chills, sweating, malaise, weight
loss, arthralgia ⁄ arthritis, hepatosplenomegaly
and lymphadenopathy [5]. Ear involvement in
brucellosis has been reported occasionally in
the literature [6,7], but few studies have evaluated
the effect of brucellosis on hearing. The aim of the
present study was to determine whether hearing
loss develops in patients with brucellosis and to
categorise any hearing loss at standard and high
frequencies.
MATERIALS AND METHODS
The study was performed in the Department of Infectious
Diseases and Clinical Microbiology at Firat University
Medical Centre between 1999 and 2002. Approval was
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granted from the local ethics committee of Firat University.
Ninety-two patients with acute brucellosis were recruited
initially, but patients were excluded on the basis of previous
hearing problems, a history of any other disorder causing
hearing loss, the presence of other systemic diseases
(diabetes mellitus, hypertension, kidney failure, etc.), a
history of ototoxic agent use, trauma to the head, or a
history of hearing loss in the family. Patients who had
received treatment for brucellosis were not included in the
study. In total, 50 patients were excluded from the study
after otoscopic and audiological examination because their
auditory system was affected by pathologies other than
brucellosis. The remaining 42 patients were evaluated
clinically, and by serological and audiological tests, before
and after treatment for brucellosis.
The diagnosis of brucellosis was made on the basis of
clinical signs and symptoms as well as laboratory findings.
The former were widespread, and included arthralgia and
myalgia, low back pain, fever, sweating and hepatospleno-
megaly. The diagnostic laboratory findings of brucellosis
included one or more of the following: isolation of the
microorganism from blood; serum Brucella agglutination test
titre (Wright test) of ‡ 1:160; or a four-fold rise in titre at
3 weeks after the onset of symptoms. A detailed physical
examination of all patients was performed. Complete and
differential blood counts, erythrocyte sedimentation rate,
rheumatoid factor levels, C-reactive protein levels and
routine biochemical studies were performed as non-specific
laboratory tests. Rifampicin 600 mg ⁄day and doxycycline
200 mg ⁄day were given for 6 weeks, and patients were
re-evaluated at 6 weeks after treatment. Decreasing levels of
C-reactive protein and decreasing erythrocyte sedimenta-
tion rates were considered to be positive responses to the
treatment protocol.
All individuals were examined by an otolaryngologist.
Hearing thresholds of all patients were evaluated before and
after therapy for 6 weeks. Standard- and high-frequency
audiometry, tympanometry and acoustic reflex tests were
performed to evaluate hearing levels. The patients were
questioned to obtain their own opinion regarding hearing
loss. Pure-tone average and speech discrimination score
assessments (using live voice and native language) were
carried out by audiometry. Pure-tone audiometric testing
was performed by the ascending method of Hughson-
Westlake [8] to determine the hearing thresholds at standard
(250–8000 Hz) and high (10 000–16 000 Hz) frequencies. The
audiometric tests were performed in a soundproof chamber
(Industrial Acoustics, San Diego, CA, USA) with an AC-40
audiometer (Interacoustics, Assens, Denmark). A TDH 39
earphone plugged into a Telephonics pillow and a Tele-
phonics KOSSHV ⁄PRO digital earphone (Interacoustics)
were used for high-frequency testing. Pure-tone audiometry
was used for all patients. Frequencies at octave intervals
from 250 to 16 000 Hz were tested for air conduction, and
from 500 to 4000 Hz for bone conduction. Hearing was
considered to be abnormal if the hearing threshold was
‡ 20 dB above the age-corrected level at two or more test
frequencies. Tympanometric tests were performed with an
AZ-26 impedance audiometer (Interacoustics) at a probe
tone frequency of 226 Hz. The tympanograms were classified
according to Jerger [9] as types A, As, Ad, B and C. The
ipsilateral and contralateral stapedius reflexes were tested
using pure tones (500–2000 Hz).
Statistical analyses were performed using SPSS for
Windows v. 10.0 (SPSS Inc., Chicago, IL, USA). The paired
Student’s t-test was used for comparing the threshold values
before and after therapy. A p value of < 0.05 was considered to
be statistically significant.
RESULTS
The 42 patients (19 females) investigated had a
mean age of 31.62 ± 13.97 years (range 14–
57 years), with 20 patients aged > 30 years. The
most common clinical manifestations were fever
(95.2%), arthralgia (90.4%), myalgia (88%) and
fatigue (88%) (Table 1). Physical examination and
laboratory findings included tinnitus in 15
(37.5%) patients, seven (16.2%) patients with
hearing loss, and three (7.1%) with a ‘filled ear’
sensation. Two (4.7%) patients had consumed
raw milk, 37 (88%) had consumed cheese pre-
pared from unpasteurised or unboiled milk, and
71.4% had a history of eating raw meatballs.
Pure-tone audiometry data were obtained
between 250 and 16 000 Hz for air, and between
500 and 4000 Hz for bone. Thresholds of
16 000 Hz were at or above the limit of the
machine in 33% of patients, so 60 dB was con-
sidered to be the threshold at 16 000 Hz for those
subjects. There was no statistically significant
difference between right and left ears, despite a
small frequency-dependent difference (p > 0.05).
In standard (250–8000 Hz) audiometry, threshold
levels of > 20 dB are considered to indicate hear-
ing loss, which was found only at 6000 and
Table 1. Clinical manifestations of 42 patients with acute
brucellosis
Symptom or sign
Patients
(n = 42) %
Fever 40 95.2
Arthralgia 38 90.4
Fatigue 37 88.0
Myalgia 37 88.0
Weakness 36 85.7
Lack of appetite 35 83.3
Sweating 34 80.9
Headache 30 71.4
Chills 29 69.0
Weight loss 29 69.0
Backache 26 61.9
Abdominal pain 19 45.2
Nausea ⁄vomiting 16 38.0
Tinnitus 15 35.7
Coughing 15 35.7
Constipation 14 33.3
Hearing loss 7 16.2
Rash 3 7.1
Fullness or pressure in the ear 3 7.1
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8000 Hz. Following treatment, thresholds of
< 20 dB were observed at 6000 and 8000 Hz
(p < 0.001) (Table 2). Pure-tone thresholds were
improved at all frequencies after treatment, and
these changes were statistically significant, except
at 12 000, 14 000 and 16 000 Hz (Table 2).
Although thresholds of > 20 dB were not
observed among patients aged < 30 years, there
were statistically significant differences between
thresholds before and after treatment at 250–
10 000 Hz. In the subgroup of patients aged
> 30 years, mean thresholds of > 20 dB were
determined at 6000 and 8000 Hz. There were no
statistically significant differences before and
after treatment in the frequency range 10 000–
16 000 Hz. Before treatment, the ratios of speech
discrimination in the right and left ears were
97.6 ± 5.4% and 98.2 ± 3.4%, respectively. After
treatment, these ratios were 98.2 ± 2.9% and
98.7 ± 3.0%, respectively; however, these differ-
ences were not statistically significant.
The pressures on the right and left ears of all
patients were found to be c. 50 mm H2O, which
was considered to be normal. Type A tympano-
gram curves were observed for all patients.
Ipsilateral and contralateral acoustic reflexes of
patients were investigated separately for right
and left sides. No statistically significant differ-
ences were observed before and after treatment.
DISCUSSION
Multisystem involvement of the gastrointestinal
tract, hepatobiliary system, skeletal system, car-
diovascular system, respiratory system, genito-
urinary tract and haematological system, as well
as cutaneous complications, may be seen in
brucellosis [10,11]. Central nervous system
involvement occurs in < 5% of cases, but brucel-
losis can cause meningitis, encephalitis, neuritis,
brain abscess, demyelinisation, transient ischae-
mic attacks, occlusive vascular disease, sensor-
ineural hearing loss, vertigo and meningovascular
syndromes [11–13]. Hearing loss in brucellosis
may develop following involvement of the central
auditory pathways [11]. Cranial nerve involve-
ment in neurobrucellosis has been found as part
of the varied neurological presentation, and it
seems that there is a predilection for the vesti-
bulo-cochlear cranial nerve, leading to sensori-
neural hearing loss [14,15].
Several studies have suggested that cerebral
inflammation caused by infections, or avascular
neural tissue resulting from reflex spasm caused
by endotoxins, can be the cause of hearing loss in
brucellosis [16–18]. Janczewski [19] reported that
Brucella endotoxin can affect the corti or VIIIth
cranial nerve directly, and that allergic factors
may contribute further to the disease process.
Janczewski [19] also detected several signs of
brucellosis, including the development of hearing
loss at the end stage of the disease, tinnitus
(which is the most common complaint) and
transient hearing loss in patients given Brucella
antigen for diagnosis and treatment. In a separate
study of 105 patients suffering from chronic
brucellosis [12], tinnitus was the most common
symptom, and 16 suffered from recurrent attacks
of vertigo. Hearing loss was found in 76 patients,
although only 64 had a documented relationship
between the hearing loss and the disease. It was
concluded that damage within the inner ear was
caused by Brucella toxin penetrating into the
labyrinth and affecting the cochlear nerve. Simi-
larly, a further study found that 93 (77.5%) of 120
patients with chronic brucellosis had hearing loss
that could be attributed to the disease [16].
Progressive hearing impairment was found in
11.7% of the patients. In the remaining patients,
therapy halted progression of the disease, while
some improvement was obtained in 15.8% of
patients. Again, it was concluded that Brucella
endotoxin and allergens were the main causes of
hearing loss. Shakir et al. [15] reported that
patients with brucellosis were affected by bilateral
sensorineural high-tone deafness, with abnormal
brain stem evoked potential. Although ataxia and
deafness nearly disappeared, and brain stem
evoked potentials returned to normal in one case,
generally the deafness was irreversible [15]. A
Table 2. Mean values of air hearing threshold audiogram
before and after therapy in patients with acute brucellosis
Test frequency (Hz)
Mean hearing threshold (dB)
Paired Student’s
t-testBefore therapy After therapy
250 14.52 ± 5.79 12.08 ± 4.80 p < 0.0001
500 12.08 ± 6.78 8.87 ± 3.59 p < 0.0001
1000 9.46 ± 4.66 7.68 ± 3.33 p < 0.0001
2000 9.40 ± 5.72 7.56 ± 4.42 p < 0.0060
4000 14.88 ± 8.78 12.32 ± 6.96 p < 0.0030
6000 22.14 ± 12.16 17.32 ± 9.64 p < 0.0001
8000 21.7 ± 11.51 16.43 ± 9.49 p < 0.0001
10 000 22.20 ± 9.83 19.35 ± 12.22 p < 0.0340
12 000 23.57 ± 12.46 21.73 ± 14.24 p > 0.2870
14 000 34.17 ± 12.07 31.96 ± 15.96 p > 0.2230
16 000 45.20 ± 12.06 43.75 ± 12.87 p > 0.4450
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mixed-type hearing loss after Brucella infection
was reported, and it was suggested that antibiotic
treatment should be started as soon as possible to
prevent irreversible ear damage [20]. In contrast,
none of the patients in the present study had a
mixed-type hearing loss at the onset of the
symptoms or during the progression of the
disease.
Bayazıt et al. [11] investigated hearing loss in
32 patients with brucellosis and reported that
brucellosis did not cause hearing loss. In the
present study, hearing loss of > 20 dB was detec-
ted only at 6000–8000 Hz. Hearing thresholds
returned to normal values at all frequencies after
treatment, and acute brucellosis did not cause
permanent hearing damage.
Some studies of the effects of brucellosis have
indicated that severe hearing loss may develop
in older patients or in patients with chronic
brucellosis [16,17,19]. In the present study, a
younger population (mean age 31.62 ±
13.97 years) was evaluated, and no permanent
hearing loss was detected. Similarly, Jezyna
et al. [21] described 150 patients with chronic
brucellosis, of whom 48% had a perceptive type
of hearing loss. This hearing loss did not
develop in patients with acute brucellosis aged
< 30 years, compared with 46% of patients
aged 31–50 years, and 68.9% of patients aged
> 50 years. It has been reported previously that
hearing loss associated with brucellosis is seen
rarely in patients aged < 30 years, but that it is
more frequent in patients aged 31–50 years [19].
Prolonged exposure to bacteria, combined with
an age of > 30 years, may increase the chance of
development of hearing loss [21,22]. In the
present study, there was no hearing loss of
> 20 dB at any frequency before treatment in
patients aged < 30 years, and hearing loss of
> 20 dB was observed only at 6000 and 8000 Hz
among the older patients. This can be explained
by the physiological changes induced by ageing
rather than the effects of acute brucellosis.
Janczewski [19] evaluated 45 patients with
chronic brucellosis who had been referred with
loss of hearing, and detected bilateral sensorineu-
ral hearing loss with almost all audiological tests
performed. The incidence of hearing loss in these
patients was increased at frequencies > 2000 Hz.
In severe cases, the hearing loss was also present
at low and medium frequencies, and individuals
sensitive to Brucella endotoxin were affected more
severely. Hearing thresholds at high frequencies
are important in indicating pathology in the basal
cochlea region (the area of high-frequency detec-
tion). Several different pathologies affecting the
distal part of the vestibulo-cochlear nerve and
cochlea are known to affect the basal region of the
cochlea. The effects of presbycusis and ototoxic
agents are observed particularly at high frequen-
cies [23]. In the present study, hearing thresholds
at high frequencies were progressive between
10 000 and 16 000 Hz before treatment. This may
be a result of the negative effects of Brucella
endotoxins in high-frequency areas of the cochlea.
Improvements at high frequencies occurred after
treatment, but these were not statistically signifi-
cant.
In conclusion, acute brucellosis affected the
hearing system, particularly at high frequencies.
Hearing thresholds improved after treatment,
although there was no apparent hearing loss with
acute brucellosis. Possible effects on the hearing
system should be considered in all forms of
brucellosis, and patients should be evaluated
carefully for hearing loss.
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